Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Minnema · SciRah

Researcher profile · Semantic Scholar

M. Minnema

Share profile

M. Minnema — researcher profile on SciRah

h-index: 56
Works: 422
Citations: 15K

Most-cited papers

International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Paula Rodríguez-Otero, S. Usmani, Adam D. Cohen, N. V. van de Donk +33 more
2024The Lancet Oncology131 citations Open access
Semantic Scholar
Zanubrutinib Versus Ibrutinib in Symptomatic Waldenström Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study
M. Dimopoulos, Stephen Samuel Opat, S. D'Sa, W. Jurczak +30 more
2023Journal of Clinical Oncology105 citations Open access
Semantic Scholar
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study.
A. Chari, C. Touzeau, C. Schinke, M. Minnema +30 more
2025The Lancet Haematology84 citations Open access
Semantic Scholar
Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
C. Schinke, C. Touzeau, M. Minnema, N. V. van de Donk +15 more
2023Journal of Clinical Oncology79 citations Open access
Semantic Scholar
Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective case series.
Nathalie Forgeard, D. Elessa, A. Carpinteiro, Karim Belhadj +16 more
2023Blood51 citations Open access
Semantic Scholar
Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
B. Shah, R. Cassaday, Jae H. Park, R. Houot +25 more
2025Leukemia45 citations Open access
Semantic Scholar
First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results.
N. V. van de Donk, Gala Vega, A. Perrot, S. Anguille +16 more
2025Journal of Clinical Oncology39 citations
Semantic Scholar
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia
Constantine S. Tam, Stephen Samuel Opat, S. D'Sa, W. Jurczak +32 more
2024Blood Advances35 citations Open access
Semantic Scholar
Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3
B. Shah, R. Cassaday, Jae H. Park, R. Houot +25 more
2023Journal for ImmunoTherapy of Cancer33 citations Open access
Semantic Scholar
Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids
Olalekan O. Oluwole, E. Forcade, J. Munoz, S. de Guibert +22 more
2024Bone Marrow Transplantation30 citations Open access
Semantic Scholar
Therapeutic drug monitoring guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: A multicentre, prospective, cluster randomised cross-over clinical trial.
A. Veringa, R. Brüggemann, L. Span, Bart J. Biemond +15 more
2023International Journal of Antimicrobial Agents26 citations Open access
Semantic Scholar
Serpin B9 controls tumor cell killing by CAR T cells
Thomas Kimman, A. Slomp, A. Martens, S. Grabherr +9 more
2023Journal for ImmunoTherapy of Cancer25 citations Open access
Semantic Scholar
Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma.
Adam Braun, Sushanth Gouni, A. Pulles, P. Strati +2 more
2024American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting22 citations
Semantic Scholar
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing
Suzanne O. Arulogun, D. Brian, H. Goradia, A. Cooney +22 more
2023American journal of hematology/oncology22 citations Open access
Semantic Scholar
Survival, neurocognitive function, and health-related quality of life outcomes after rituximab—methotrexate, BCNU, teniposide, and prednisolone for primary CNS lymphoma: Final results of the HOVON 105/ALLG NHL 24 study
J. Bromberg, S. Issa, B. van der Holt, M. van der Meulen +16 more
2023Neuro-Oncology21 citations Open access
Semantic Scholar
R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
M. Chamuleau, F. Stenner, D. Chitu, U. Novak +27 more
2023The Lancet Haematology20 citations Open access
Semantic Scholar
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial
Roberto Mina, A. Mylin, Hisayuki Yokoyama, H. Magen +21 more
2025The Lancet Haematology19 citations
Semantic Scholar
Clinical Outcomes of Subsequent Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 MonumenTAL-1 Study
Larysa J. Sanchez, C. Schinke, Amrita Y. Krishnan, J. Berdeja +21 more
2023Blood18 citations Open access
Semantic Scholar
Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study
E. Kastritis, G. Palladini, M. Minnema, A. Wechalekar +26 more
2024Blood16 citations
Semantic Scholar
Dose selection of novel anticancer drugs: exposing the gap between selected and required doses.
Catharina J. P. Op 't Hoog, N. Mehra, M. Maliepaard, K. Bol +8 more
2024The Lancet Oncology15 citations Open access
Semantic Scholar
S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
C. Touzeau, C. Schinke, M. Minnema, N. V. van de Donk +15 more
2023HemaSphere15 citations Open access
Semantic Scholar
Zanubrutinib in Bing Neel syndrome: efficacy and tolerability
A. Becking, J. V. D. van de Mortel, O. Tomkins, T. Flinsenberg +14 more
2025Leukemia14 citations Open access
Semantic Scholar
Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation
Thomas Kimman, Marta Cuenca, R. Tieland, Dedeke Rockx-Brouwer +18 more
2025Nature Communications13 citations Open access
Semantic Scholar
New Validated Staging System for Light Chain (AL) Amyloidosis With Stage IIIC Defining Ultra-Poor Risk: AL International Staging System
J. Khwaja, A. Kirkwood, P. Milani, B. Yohannan +25 more
2025Journal of Clinical Oncology13 citations Open access
Semantic Scholar
MM-492 Long-term Efficacy and Safety Results From the Phase 1/2 MonumenTAL-1 Study of Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
L. Rasche, C. Schinke, C. Touzeau, M. Minnema +15 more
2024Clinical Lymphoma, Myeloma & Leukemia12 citations
Semantic Scholar
Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light-Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
E. Kastritis, M. Minnema, M. Dimopoulos, G. Merlini +8 more
2023Blood12 citations Open access
Semantic Scholar
Report of consensus panel 2 from the 12th international workshop on the management of Bing-Neel syndrome in patients with Waldenstrom's Macroglobulinemia.
S. Sarosiek, A. Becking, A. Branagan, Simone Ferrero +11 more
2025Seminars in hematology (Print)9 citations
Semantic Scholar
Cryoglobulinemic Vasculitis in Disguise: Cryofibrinogenemia as Variant of Monoclonal Gammopathy of Renal Significance.
Christina M. Gant, C. Koelman, Tri Q. Nguyen Tq, A. Abrahams +7 more
2023American Journal of Kidney Diseases9 citations Open access
Semantic Scholar
The Role of Complement Activation in IgM M-Protein–Associated Neuropathies
J. V. D. van de Mortel, K. Budding, Kim Dijkxhoorn, M. Minnema +3 more
2024Neurology(R) neuroimmunology & neuroinflammation8 citations Open access
Semantic Scholar
Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network
E. Kastritis, M. Minnema, M. Dimopoulos, G. Merlini +9 more
2024Blood7 citations
Semantic Scholar
Efficacy and safety from the phase 1/2 MonumenTAL-1 study of talquetamab, a GPRC5D×CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: Analyses at an extended median follow-up.
L. Rasche, C. Schinke, C. Touzeau, M. Minnema +16 more
2025Journal of Clinical Oncology6 citations
Semantic Scholar
Efficacy and safety in early-phase clinical trials for refractory colorectal cancer: A meta-analysis.
L. Smabers, Maarten A. Huismans, Niels van Nieuwenhuijzen, M. Minnema +5 more
2024European Journal of Cancer6 citations Open access
Semantic Scholar
Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study.
J. V. van Rooij, Peter H. Wessels, J. Niers, J. Bromberg +16 more
2026The Lancet Haematology5 citations
Semantic Scholar
Prognostic value of premaintenance FDG PET/CT response in patients with newly diagnosed myeloma from the CASSIOPEIA trial
F. Kraeber-Bodéré, B. Jamet, S. Zweegman, A. Perrot +17 more
2025Blood5 citations Open access
Semantic Scholar
The Diagnostic Yield of Cerebrospinal Fluid Analysis for the Diagnosis of Primary Central Nervous System Lymphoma: A Systematic Review
J. V. van Rooij, Tom J. Snijders, Prerana Bhande, Tatjana Seute +2 more
2025Cancers5 citations Open access
Semantic Scholar
Daratumumab-Bortezomib-Cyclophosphamide-Dexamethasone in Newly Diagnosed Amyloidosis: ANDROMEDA Final Survival Analysis.
E. Kastritis, Giovannni Palladini, M. Minnema, A. Wechalekar +41 more
2026Blood4 citations Open access
Semantic Scholar
Acalabrutinib in Waldenström macroglobulinemia yields durable responses with 5 years of follow-up
R. Owen, Helen McCarthy, S. D'Sa, S. Thomas +15 more
2026Blood Advances4 citations Open access
Semantic Scholar
Uncovering cell type-specific phenotypes using a novel human in vitro model of transthyretin amyloid cardiomyopathy
J. Qin, Qiang-Bing Yang, A. Ullate-Agote, V. Sampaio-Pinto +18 more
2025Stem cell research & therapeutics4 citations Open access
Semantic Scholar
Report of Consensus Panel 5 from the 12th International Workshop on Waldenström's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors.
J. Castillo, F. Autore, Neil L. Berinstein, A. Branagan +15 more
2025Seminars in hematology (Print)4 citations Open access
Semantic Scholar
Complement activation by IgM autoantibodies linked to immune‐mediated neuropathies depends on C2
K. Budding, Kim Dijkxhoorn, Elisabeth de Zeeuw, Lauri M. Bloemenkamp +6 more
2024European Journal of Neurology4 citations Open access
Semantic Scholar
Recent updates in the indolent lymphomas: Update on marginal zone lymphoma and Waldenström's macroglobulinemia
K. Amaador, C. Thieblemont, J. Trotman, M. Minnema
2023Hematological Oncology4 citations Open access
Semantic Scholar
Phase 1/1b study of BCMA-targeting bispecific T-cell engager pavurutamab in relapsed/refractory multiple myeloma.
Hans C. Lee, W. Plattel, Simon J. Harrison, Doug Sborov +15 more
2026Blood3 citations Open access
Semantic Scholar
MM-906: First-in-Human Study of JNJ-79635322 (JNJ-5322), a Novel Next-Generation Trispecific Antibody, in Patients With Relapsed/Refractory Multiple Myeloma: Initial Phase 1 Results
Hans Lee, R. Popat, C. Touzeau, A. Perrot +31 more
2025Clinical Lymphoma, Myeloma & Leukemia3 citations
Semantic Scholar
In vitro and in vivo disease models of cardiac amyloidosis: progress, pitfalls, and potential
J. Qin, Ze-Ping Qiu, Yingze Fan, Qipeng Xiong +7 more
2025Cardiovascular Research3 citations Open access
Semantic Scholar
Automated vertebrae identification and segmentation with structural uncertainty analysis in longitudinal CT scans of patients with multiple myeloma.
Djennifer K. Madzia-Madzou, M. Jak, B. de Keizer, J. Verlaan +2 more
2025European Journal of Radiology3 citations Open access
Semantic Scholar
New biomarkers for the diagnosis of primary central nervous system lymphoma in CSF: A multicenter retrospective cohort study
J. V. van Rooij, Peter H. Wessels, E. Delemarre, Bob Meek +5 more
2025Neuro-Oncology Advances3 citations Open access
Semantic Scholar
Updated efficacy and safety results of JNJ-5322, a novel, next-generation BCMA×GPRC5D×CD3 trispecific antibody, in patients with Relapsed/Refractory multiple myeloma
Amrita Y. Krishnan, Martin F. Kaiser, R. Popat, J. Matous +34 more
2025Blood3 citations Open access
Semantic Scholar
Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.
Olalekan O. Oluwole, A. Ghobadi, R. Cassaday, Jae H. Park +16 more
2024Journal of Clinical Oncology3 citations Open access
Semantic Scholar
Outcomes of patients aged ≥26 years with relapsed or refractory B-cell acute lymphoblastic leukemia in ZUMA-3 and historical trials
M. Minnema, Xiang Yin, Ruthanna C Davi, S. Keeping +8 more
2024Leukemia and Lymphoma3 citations Open access
Semantic Scholar
Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: An Updated Analysis of a Phase 2 Study By the European Myeloma Network
E. Kastritis, G. Palladini, M. Dimopoulos, A. Jaccard +10 more
2024Blood3 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

N. V. van de Donk×11
Invite
N. V. van de Donk — researcher profile on SciRah
E. Kastritis×10
Invite
E. Kastritis — researcher profile on SciRah
C. Touzeau×10
Invite
C. Touzeau — researcher profile on SciRah
J. Matous×7
Invite
J. Matous — researcher profile on SciRah

P. Rodríguez-Otero

×7

Invite

P. Rodríguez-Otero — researcher profile on SciRah

Lionel Karlin×7

Invite

Lionel Karlin — researcher profile on SciRah

Invite

B. Hilder — researcher profile on SciRah

Invite

A. Chari — researcher profile on SciRah

Invite

C. Schinke — researcher profile on SciRah

Invite

L. Rasche — researcher profile on SciRah

D. Vishwamitra×6

Invite

D. Vishwamitra — researcher profile on SciRah

Invite

M. Campagna — researcher profile on SciRah